Compare DexCom, Inc. (DXCM) vs Procter & Gamble Co (PG) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Procter & Gamble (PG) trades at $146.12, down 1.52% with bearish technical signals but strong fundamentals. The company maintains consistent revenue growth, with 2025 revenue reaching $84.28B and net income of $15.97B. Recent earnings have consistently beaten expectations, and analyst consensus remains positive with a $161.71 price target. Dividend payments continue with $1.09 per share payouts, supporting income-focused investors amid market volatility.

PG offers stability with 69 consecutive years of dividend growth and efficient cash flow generation, though premium valuation multiples and modest growth outlook present near-term headwinds. The stock's technical weakness contrasts with fundamental strength, creating potential for recovery if earnings momentum continues. Key risks include consumer demand softness and competitive pressures in the consumer staples sector.